{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:47:49Z","timestamp":1780343269889,"version":"3.54.1"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jns.2018.02.028","type":"journal-article","created":{"date-parts":[[2018,2,19]],"date-time":"2018-02-19T12:14:27Z","timestamp":1519042467000},"page":"222-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment"],"prefix":"10.1016","volume":"388","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8138-7504","authenticated-orcid":false,"given":"Seyed Mohammad","family":"Baghbanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdorreza Naser","family":"Moghadasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2018.02.028_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2018.02.028_bb0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jnnp-2014-308550","article-title":"Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features","volume":"86","author":"Absoud","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.028_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0020","doi-asserted-by":"crossref","first-page":"e1039","DOI":"10.1542\/peds.2007-2758","article-title":"Spectrum of pediatric neuromyelitis optica","volume":"122","author":"Lotze","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jns.2018.02.028_bb0025","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jns.2018.02.028_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1212\/WNL.0000000000002283","article-title":"Clinical features of neuromyelitis optica in children: US network of pediatric MS centers report","volume":"86","author":"Chitnis","year":"2016","journal-title":"Neurology"},{"issue":"19","key":"10.1016\/j.jns.2018.02.028_bb0045","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1212\/WNL.0b013e3181fc2823","article-title":"Neuromyelitis optica and NMO-IgG in European pediatric patients","volume":"75","author":"Huppke","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pediatrneurol.2013.07.003","article-title":"Neuromyelitis optica with onset in childhood and adolescence","volume":"50","author":"Fragoso","year":"2014","journal-title":"Pediatr. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.02.028_bb0055","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jnnp-2014-308550","article-title":"Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features","volume":"86","author":"Absoud","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.jns.2018.02.028_bb0060","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","article-title":"Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease","volume":"87","author":"Lechner","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.028_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archophthalmol.2007.26","article-title":"Clinical course of optic neuritis in patients with relapsing neuromyelitis optica","volume":"126","author":"Papais-Alvarenga","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jns.2018.02.028_bb0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jns.2018.02.028_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/IIO.0b013e318259dec6","article-title":"Pediatric optic neuritis","volume":"52","author":"El-Dairi","year":"2012","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.jns.2018.02.028_bb0080","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0085","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0361-9230(92)90013-N","article-title":"Subnuclear organization of the human caudal nucleus of the solitary tract","volume":"29","author":"Hyde","year":"1992","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jns.2018.02.028_bb0110","series-title":"Circurnventricular Organs and Body Fluids: Modulation of the Visceral Neuraxis","first-page":"143","volume":"vol 3","author":"Miselis","year":"1987"},{"issue":"5","key":"10.1016\/j.jns.2018.02.028_bb0115","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1590\/S0004-282X2011000600019","article-title":"Atypical presentations of neuromyelitis optica","volume":"69","author":"Sato","year":"2011","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.jns.2018.02.028_bb0120","series-title":"Poster Presented at the Annual Meeting of the American Academy of Neurology","article-title":"Aquaporin-4 antibody positive male patients: an analysis of 144 cases","author":"Sato","year":"2011"},{"key":"10.1016\/j.jns.2018.02.028_bb0125","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/01.wnl.0000183151.19351.82","article-title":"Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica","volume":"65","author":"Misu","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0130","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e318214332c","article-title":"Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications","volume":"76","author":"Popescu","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ncn3.12052","article-title":"Fulminant case of neuromyelitis optica spectrum disorder initiated with area postrema symptoms","volume":"4","author":"Takahashi","year":"2016","journal-title":"Neurol Clin Neurosci"},{"key":"10.1016\/j.jns.2018.02.028_bb0140","series-title":"Area Postrema Syndrome more Specific than Extension of Lesion on MRI for Neuromyelitis Optica Spectrum disorder neurology","volume":"vol. 88","author":"Dubey","year":"2017"},{"issue":"3","key":"10.1016\/j.jns.2018.02.028_bb0145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaneurol.2016.5441","article-title":"Association of extension of cervical cord lesion and area Postrema syndrome with Neuromyelitis Optica Spectrum disorder","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pediatrneurol.2017.02.002","article-title":"Pediatric multiple sclerosis presenting as area Postrema syndrome","volume":"70","author":"Vila-Bedmar","year":"2017","journal-title":"Pediatr. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2018.02.028_bb0155","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00415-009-5171-x","article-title":"Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution","volume":"256","author":"Bizzoco","year":"2009","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2018.02.028_bb0160","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jocn.2010.12.052","article-title":"Prominent brainstem symptoms\/signs in patients with neuromyelitis optica in a Taiwanese population","volume":"18","author":"Wang","year":"2011","journal-title":"J. Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.jns.2018.02.028_bb0165","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0170","first-page":"1287690","article-title":"Acute respiratory failure due to Neuromyelitis Optica treated successfully with plasmapheresis","volume":"2016","author":"Zantah","year":"2016","journal-title":"Case Rep Pulmonol."},{"issue":"3","key":"10.1016\/j.jns.2018.02.028_bb0175","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/WNO.0b013e31821d549b","article-title":"Ocular oscillations in the neuromyelitis optica spectrum","volume":"31","author":"Hage","year":"2011","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jns.2018.02.028_bb0180","first-page":"73","article-title":"Trigeminal autonomic cephalalgia as a presenting feature of Neuromyelitis Optica: a rare combination of two uncommon disorders, Mult Scler Relat Disord","volume":"6","author":"Mathew","year":"2016","journal-title":"Mar"},{"key":"10.1016\/j.jns.2018.02.028_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-219721","article-title":"Syndrome of inappropriate antidiuretic hormone accompanied by bilateral hypothalamic and anterior thalamic lesions with serum antiaquaporin 4 antibody","author":"Inoue","year":"2017","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0190","doi-asserted-by":"crossref","first-page":"100","DOI":"10.23876\/j.krcp.2017.36.1.100","article-title":"Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder","volume":"36","author":"Oh","year":"2017","journal-title":"Kidney Res Clin Pract."},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00415-014-7537-y","article-title":"Syndrome of inappropriate antidiuretic hormone secretion in patients with aquaporin-4 antibody","volume":"262","author":"Pu","year":"2015","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2018.02.028_bb0200","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1177\/1352458514536254","article-title":"Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient","volume":"20","author":"Kravljanac","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0205","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000334129","article-title":"Antiaquaporin-4 antibody-positive neuromyelitis optica presenting with syndrome of inappropriate antidiuretic hormone secretion as an initial manifestation","volume":"3","author":"Nakajima","year":"2011","journal-title":"Case Rep Neurol."},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.23876\/j.krcp.2017.36.1.100","article-title":"Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder","volume":"36","author":"Oh","year":"2017","journal-title":"Kidney Res Clin Pract."},{"key":"10.1016\/j.jns.2018.02.028_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-219721","article-title":"Syndrome of inappropriate antidiuretic hormone accompanied by bilateral hypothalamic and anterior thalamic lesions with serum antiaquaporin 4 antibody","author":"Inoue","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.jns.2018.02.028_bb0220","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1191\/1352458505ms1200cr","article-title":"Neuromyelitis optica with hypothalamic involvement","volume":"11","author":"Poppe","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0225","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00415-009-0139-4","article-title":"Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody","volume":"256","author":"Baba","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0230","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/1352458510376640","article-title":"Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity","volume":"16","author":"Kim","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0235","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0240","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1352458506070725","article-title":"Brain magnetic resonance imaging findings in relapsing neuromyelitis optica","volume":"13","author":"Cabrera-Gomez","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0245","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1743-8454-7-15","article-title":"Aquaporins: relevance to cerebrospinal fluid physiology and therapeutic potential in hydrocephalus","volume":"7","author":"Owler","year":"2010","journal-title":"Cerebrospinal Fluid Res."},{"key":"10.1016\/j.jns.2018.02.028_bb0250","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1212\/WNL.0000000000000428","article-title":"Hydrocephalus in neuromyelitis optica","volume":"82","author":"Clardy","year":"2014","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2018.02.028_bb0255","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder. An international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0260","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.0b013e3182703ff7","article-title":"Two cases of lumbosacral myeloradiculitis with anti-aquaoporin-4 antibody","volume":"79","author":"Takai","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2018.02.028_bb0265","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/s10165-011-0438-3","article-title":"Nakagomi D, et al, a patient with neuromyelitis optica with positive anti-Ro (SS-A) antibody presenting with intractable hiccup and nausea","volume":"21","author":"Koga","year":"2011","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0270","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pediatrneurol.2006.07.008","article-title":"Primary Sj\u00f6grens syndrome presenting as neuromyelitis optica","volume":"36","author":"G\u00f6k\u00e7ay","year":"2007","journal-title":"Pediatr. Neurol."},{"issue":"20","key":"10.1016\/j.jns.2018.02.028_bb0275","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2018.02.028_bb0280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.msard.2013.01.003","article-title":"Myasthenia gravis and neuromyelitis opica: a causal link","volume":"2","author":"Spillane","year":"2013","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"10.1016\/j.jns.2018.02.028_bb0285","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/1352458507084107","article-title":"Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome","volume":"14","author":"Mehta","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0290","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archneur.65.5.629","article-title":"Aquaporin-4 autoantibodies in a paraneoplastic context","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0295","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1179\/2045772312Y.0000000018","article-title":"Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: favorable response to cancer treatment","volume":"35","author":"Armagan","year":"2012","journal-title":"J Spinal Cord Med."},{"key":"10.1016\/j.jns.2018.02.028_bb0300","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10072-009-0112-0","article-title":"A possible paraneoplastic neuromyelitis optica associated with lung cancer","volume":"30","author":"De Santis","year":"2009","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jns.2018.02.028_bb0305","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jneuroim.2013.07.003","article-title":"Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma","volume":"263","author":"Frasquet","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jns.2018.02.028_bb0310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.hemonc.2014.06.001","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder associated with stomach carcinoid tumor","volume":"7","author":"Al-Harbi","year":"2014","journal-title":"Hematol Oncol Stem Cell Ther."},{"key":"10.1016\/j.jns.2018.02.028_bb0315","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2018.02.028_bb0320","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jns.2018.02.028_bb0325","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1172\/JCI231","article-title":"Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4","volume":"100","author":"Ma","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jns.2018.02.028_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-386043-9.00001-3","article-title":"Structure and functions of aquaporin-4-based orthogonal arrays of particles","volume":"287","author":"Wolburg","year":"2011","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.jns.2018.02.028_bb0335","doi-asserted-by":"crossref","first-page":"11981","DOI":"10.1073\/pnas.95.20.11981","article-title":"Direct immunogold labeling of aquaporin-4 in square arrays of astrocyte and ependymocyte plasma membranes in rat brain and spinal cord","volume":"95","author":"Rash","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2018.02.028_bb0340","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1523\/JNEUROSCI.17-01-00171.1997","article-title":"Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain","volume":"17","author":"Nielsen","year":"1997","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.jns.2018.02.028_bb0345","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0350","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-med-043010-193843","article-title":"Aquaporins in clinical medicine","volume":"63","author":"Verkman","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jns.2018.02.028_bb0355","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2018.02.028_bb0360","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0365","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1756285611398939","article-title":"Current and future treatment approaches for neuromyelitis optica","volume":"4","author":"Collongues","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2018.02.028_bb0370","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jns.2018.02.028_bb0375","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0380","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","article-title":"Neutrophil protease inhibition reduces NMO-IgG-induced damage in mouse brain","volume":"71","author":"Saadoun","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0385","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1093\/brain\/awq177","article-title":"Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury","volume":"133","author":"Marignier","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.02.028_bb0390","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.02.028_bb0395","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/brain\/awf087","article-title":"Contrastenhanced MRI in acute optic neuritis: relationship to visual performance","volume":"125","author":"Kupersmith","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.02.028_bb0400","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNO.0b013e318254c62d","article-title":"Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis","volume":"32","author":"Khanna","year":"2012","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jns.2018.02.028_bb0405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/WNO.0b013e318283c3ed","article-title":"Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system","volume":"33","author":"Storoni","year":"2013","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jns.2018.02.028_bb0410","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2377-13-33","article-title":"Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a populationbased, descriptive study","volume":"13","author":"Asgari","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0415","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neurad.2008.12.008","article-title":"MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis","volume":"36","author":"Cassinotto","year":"2009","journal-title":"J. Neuroradiol."},{"key":"10.1016\/j.jns.2018.02.028_bb0420","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00415-008-0545-z","article-title":"Preferential spinal central gray matter involvement in neuromyelitis optica: an MRI study","volume":"255","author":"Nakamura","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0425","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0430","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","article-title":"Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders","volume":"70","author":"Banwell","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0435","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.02.028_bb0440","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.60.4.382","article-title":"Clinical, CSF, and MRI findings in Devic's neuromyelitis optica","volume":"60","author":"O'Riordan","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.028_bb0445","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1212\/WNL.53.8.1705","article-title":"MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica","volume":"53","author":"Filippi","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0450","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0455","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0460","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/1352458510376640","article-title":"Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity","volume":"16","author":"Kim","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0465","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejrad.2010.06.024","article-title":"Brain MRI abnormalities in neuromyelitis optica","volume":"80","author":"Wang","year":"2011","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.jns.2018.02.028_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/S0004-282X2008000100001","article-title":"Neuromyelitis optica: brain abnormalities in a Brazilian cohort","volume":"66","author":"Bichuetti","year":"2008","journal-title":"Arq. Neuropsiquiatr."},{"issue":"4","key":"10.1016\/j.jns.2018.02.028_bb0475","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jnnp-2014-308550","article-title":"Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features","volume":"86","author":"Absoud","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.028_bb0480","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/WNL.0b013e3181f39a66","article-title":"Long-term follow-up of neuromyelitis optica with a pediatric onset","volume":"75","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0485","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1352458509103301","article-title":"Occurrence of acute large and edematous callosal lesions in neuromyelitis optica","volume":"15","author":"Nakamura","year":"2009","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.jns.2018.02.028_bb0490","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0495","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jns.2010.01.009","article-title":"Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status","volume":"291","author":"Matsushita","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2018.02.028_bb0500","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","article-title":"Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders","volume":"72","author":"Magana","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0505","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/archneurol.2007.59","article-title":"Acute disseminating encephalomyelitis in neuromyelitis optica: closing the floodgates","volume":"65","author":"Eichel","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0510","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0883073812443006","article-title":"Masquerades of acquired demyelination in children: experiences of a national demyelinating disease program","volume":"28","author":"O'Mahony","year":"2013","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0515","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.21753","article-title":"\u201cCloud-like enhancement\u201d is a magnetic resonance imaging abnormality specific to neuromyelitis optica","volume":"66","author":"Ito","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0520","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0525","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/practneurol-2012-000237","article-title":"A practical guide to the treatment of neuromyelitis optica","volume":"12","author":"Palace","year":"2012","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0530","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0535","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0540","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","article-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","volume":"15","author":"Bonnan","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0545","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Magana","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0550","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels","volume":"9","author":"Kim","year":"2013","journal-title":"J Clin Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0555","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/1352458512471875","article-title":"Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders","volume":"19","author":"Lim","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0560","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jocn.2010.05.030","article-title":"The rescue effect of plasma exchange for neuromyelitis optica","volume":"18","author":"Wang","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2018.02.028_bb0565","first-page":"787630","article-title":"Plasma exchange in severe attacks of neuromyelitis optica","volume":"2012","author":"Bonnan","year":"2012","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.jns.2018.02.028_bb0570","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0575","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.jns.2018.02.028_bb0580","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/14737175.2016.1150178","article-title":"Therapeutic options in neuromyelitis optica spectrum disorders","volume":"16","author":"Kitley","year":"2016","journal-title":"Expert. Rev. Neurother."},{"issue":"6","key":"10.1016\/j.jns.2018.02.028_bb0585","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.pcl.2013.08.006","article-title":"Pediatric therapeutic apheresis: rationale and indications for plasmapheresis, cytapheresis, extracorporeal photopheresis, and LDL apheresis","volume":"60","author":"Kim","year":"2013","journal-title":"Pediatr. Clin. N. Am."},{"issue":"12","key":"10.1016\/j.jns.2018.02.028_bb0590","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1542\/pir.25-12-425","article-title":"Chronic steroid and immunosuppressant therapy in children","volume":"25","author":"Gedalia","year":"2004","journal-title":"Pediatr. Rev."},{"key":"10.1016\/j.jns.2018.02.028_bb0595","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis","volume":"56","author":"Noseworthy","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0600","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.02.028_bb0605","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.jns.2018.02.028_bb0610","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0615","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0620","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/pgs.09.155","article-title":"Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?","volume":"11","author":"Higgs","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jns.2018.02.028_bb0625","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0630","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.jns.2018.02.028_bb0635","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/rheumatology\/kei263","article-title":"Sustained improvement of a girl affected with Devic's disease over 2\u202fyears of mycophenolate mofetil treatment","volume":"45","author":"Falcini","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.jns.2018.02.028_bb0640","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdg175","article-title":"An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab","volume":"14","author":"Boye","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jns.2018.02.028_bb0645","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0650","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of fcgr3a polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0655","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"6","key":"10.1016\/j.jns.2018.02.028_bb0660","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of Rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0665","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"G\u00fcrcan","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jns.2018.02.028_bb0670","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0675","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"Zaheer","year":"2012","journal-title":"Ther Adv Drug Saf."},{"key":"10.1016\/j.jns.2018.02.028_bb0680","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1212\/WNL.0b013e3181f39a66","article-title":"Long-term follow-up of neuromyelitis optica with a pediatric onset","volume":"75","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0685","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2018.02.028_bb0690","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1212\/WNL.0b013e31826845fe","article-title":"Does natalizumab therapy worsen neuromyelitis optica?","volume":"79","author":"Jacob","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0695","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0700","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"issue":"9","key":"10.1016\/j.jns.2018.02.028_bb0705","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458517694086","article-title":"Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Yamout","year":"2017","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.jns.2018.02.028_bb0710","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1177\/1352458517703803","article-title":"Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?","volume":"23","author":"Kira","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0715","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"issue":"5","key":"10.1016\/j.jns.2018.02.028_bb0720","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrneurol.2015.53","article-title":"Multiple sclerosis and pregnancy in the \u2018treatment era\u2019","volume":"11","author":"Vukusic","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2018.02.028_bb0725","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1007\/s00415-013-7031-y","article-title":"Neuromyelitis optica and pregnancy","volume":"260","author":"Fragoso","year":"2013","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2018.02.028_bb0730","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/1352458515583376","article-title":"Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder","volume":"22","author":"Shimizu","year":"2016","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0735","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","article-title":"Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"86","author":"Nour","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.028_bb0740","series-title":"Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk","author":"Briggs","year":"2012"},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0745","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/gast.2003.50014","article-title":"The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study","volume":"124","author":"Francella","year":"2003","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jns.2018.02.028_bb0750","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13760-016-0654-x","article-title":"Neuromyelitis optica and pregnancy","volume":"116","author":"Zare-Shahabadi","year":"2016","journal-title":"Acta Neurol Belg."},{"key":"10.1016\/j.jns.2018.02.028_bb0755","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/BOR.0000000000000055","article-title":"Rheumatoid arthritis medications and lactation","volume":"26","author":"Sammaritano","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jns.2018.02.028_bb0760","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","article-title":"Influence of pregnancy on neuromyelitis optica spectrum disorder","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0765","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jns.2009.08.040","article-title":"Association of anti-aquaporin-4 antibodypositive neuromyelitis optica with myasthenia gravis","volume":"287","author":"Uzawa","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.jns.2018.02.028_bb0770","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0883073809343316","article-title":"Marked hypotonia in an infant of a mother with Devic disease","volume":"25","author":"Zifman","year":"2010","journal-title":"J. Child Neurol."},{"issue":"4","key":"10.1016\/j.jns.2018.02.028_bb0775","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jns.2018.02.028_bb0780","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.jns.2018.02.028_bb0785","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","article-title":"Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease","volume":"87","author":"Lechner","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.028_bb0790","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2018.02.028_bb0795","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0800","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jns.2018.02.028_bb0805","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflammation"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T01:03:13Z","timestamp":1570755793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18300856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":158,"alternative-id":["S0022510X18300856"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.028","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}